StreetAlpha.app
Home › Stocks › QNRX

Quoin Pharmaceuticals Ltd. (QNRX)

$3.28
▼ −2.35%
LAST CLOSE · NOV 20

Quoin Pharmaceuticals develops topical drug candidates for rare genetic skin diseases, led by a lotion for Netherton Syndrome. It last closed at $3.28 on Nov 20, down 2.35% on the day. The next earnings report for QNRX is expected around Thu, Mar 25, 2027. Over its last 8 reports the stock moved an average of 5.8% the session after earnings. Over the last 12 months QNRX insiders bought $280K of stock on the open market and sold $0, according to SEC Form 4 filings.

AI Auto Pilots
Is QNRX in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold QNRX.

Key Stats

Last 12 months
Results
Net income
−$19.6M
Valuation
Market cap
$230.6M
70.3M shares
P/E
–
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$10.1M
At Sep 30
Shareholder equity
$28.7M
Shares outstanding
70.3M
At Aug 12
ExchangeNasdaq
Financials history
FY2021: −$21.5M−$21.5MFY2021FY2022: −$9.4M−$9.4MFY2022FY2023: −$8.7M−$8.7MFY2023FY2024: −$9.0M−$9.0MFY2024FY2025: −$15.8M−$15.8MFY2025

From QNRX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
Mar 25
Estimated date · Time not announced
Reported EPS
—
Not on file yet
Year ago EPS
—
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Not enough quarters on file yet.
Revenue by quarter
Not enough quarters on file yet.
How QNRX moved after its last 8 reports
Average move the session after a report ±5.8%
Nov 6, 2026After the close+7.0%
Aug 14, 2026After the close+2.0%
May 7, 2026After the close−6.9%
Mar 26, 2026Time not announced−18.4%
Nov 6, 2025After the close+5.1%
Aug 7, 2025After the close+3.5%
May 14, 2025After the close+0.7%
Mar 13, 2025After the close+3.2%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on QNRXStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on QNRX
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on QNRX

Technical Analysis

QNRX · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold

The stock is 16% below its 20 day and 41% below its 50 day average. It is 72% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 33), near oversold. The nearest support is the swing low (Jun 23) at $3.25, and the nearest resistance the Pivot at $3.37.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityNormal, 10.0%/day
Key levels
$23.5052 week high+616.5%
$5.65200 day average+72.3%
$4.89100 day average+49.1%
$4.6450 day average+41.5%
$3.99Swing high (Nov 13)+21.6%
$3.8120 day average+16.2%
$3.55Pivot R1+8.2%
$3.37Pivot+2.7%
$3.28Last close
$3.25Swing low (Jun 23)−0.9%
$3.1852 week low−3.0%
$3.09Pivot S1−5.8%
Indicators
RSI (14)32.69Weak, oversold below 30Neutral
MACD-0.31Below its signal lineBearish
Stochastic13.1Near the bottom of its rangeOversold
ADX (14)24.5Weak trend
Williams %R-91.4Oversold below −80, overbought above −20Oversold
CCI (20)-139.4Oversold below −100, overbought above 100Oversold
Rate of change−10.1%Change over 10 sessionsBearish
ATR (14)$0.33Typical daily range, 10.0% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for QNRX

What happened before

See how QNRX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow QNRX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How QNRX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2016.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for QNRXHow many large options trades hit QNRX, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

QNRX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲20 buying vs 11 selling
  • ▲Held by funds +2.0 pts
  • ▲Funds holding +6
  • ▲Superinvestors: 2 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding2519+31.6%
In funds' top 1000–
Held by funds3.8%1.9%+2.0 pts
New / increased15 / 51 / 9+100.0%
Reduced / sold out2 / 93 / 3+83.3%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See QNRX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

QNRX Insider Trading

All filings →
Insider trading · 12 months
Insiders are net buyers
Bought$280K4 buys · 4 insiders
Sold$00 sales · 0 insiders
Cluster buy: 4 insiders bought $280K between Aug 31 and Aug 31.
2026-08 bought $280KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Aug 31Anthony James CulverwellDirectorBuy6,146$4.88$30K
Aug 31Sally Bridget LawlorCFOBuy10,244$4.88$50K
Aug 31Michael MyersCEOBuy20,490$4.88$100K
Aug 31Denise P. CarterCOOBuy20,490$4.88$100K
Oct 14, 2025Dennis LangerDirectorBuy15,152$8.49$129K
Dec 23, 2024Anthony James CulverwellDirectorBuy100,000$0.45$45K
Every insider buy and sale for QNRX over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See QNRX insider trades →

From SEC Form 4 filings by QNRX's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether QNRX is in one of them and how their past QNRX trades turned out.

QNRX in the AI portfolios
Loading…

QNRX News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered QNRX in an article yet. Here's the latest on the wider market.

QNRX in the news

About Quoin Pharmaceuticals

Quoin Pharmaceuticals is a specialty drug developer based in Ashburn, Virginia. It focuses on treatments for rare and orphan diseases that have few or no approved options. Its lead product candidate, QRX003, is a topical lotion in clinical testing for Netherton Syndrome, a rare genetic skin disease, and it is also being studied for other rare skin conditions. The company plans to sell its products to patients and healthcare providers in the United States, Europe and Japan, and works with distribution partners in other countries. It has not yet commercialized any products.

Headquarters
Ashburn, VA